Cover Image

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration

Background: Spironolactone is an off-label acne treatment that is commonly prescribed due to its low cost, efficacy, and tolerability. Objective: This study aimed to classify the most common adverse reactions associated with spironolactone in women of all ages and analyze the relative risk of hyperk...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu Wang, BA (Author), Shari R. Lipner, MD, PhD (Author)
Format:	Book
Published:	Wolters Kluwer, 2020-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021
by: Christine Learned, BA, et al.
Published: (2022)

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases
by: Menglin He, et al.
Published: (2024)

Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study
by: Jingying Wu, et al.
Published: (2024)

Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program
by: Rebecca M. Thiede, et al.
Published: (2019)

Keep an Eye on At-Home Devices: Energy-Based Acne and Anti-Aging Devices are Associated with Ocular Adverse Events in a Retrospective Analysis Using the MAUDE Database
by: Rachel C Hill, et al.
Published: (2024)

Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
by: Yi Zheng, et al.
Published: (2023)

Spironolactone for the treatment of acne in women, a retrospective study of 110 patients
by: J.W. Charny, BS, et al.
Published: (2017)

Variation in adverse drug events of opioids in the United States
by: Edward Y. Liu, et al.
Published: (2023)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
by: Ying Zhang, et al.
Published: (2023)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
by: Jun Wang, et al.
Published: (2023)

Spironolactone in hidradenitis suppurativa: a single-center
by: Rahul Masson, BS, et al.
Published: (2024)

Case series of reports of pruritus and sipuleucel-T submitted to the Food and Drug Administration Adverse Event Reporting System
by: Graça M. Dores, et al.
Published: (2019)

Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis
by: Zhou, Zeyun, et al.
Published: (2020)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
by: Xiaoyin Bai, et al.
Published: (2021)

Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: A cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS)
by: Samuel Yeroushalmi, BS, et al.
Published: (2022)

Liver injury in children: signal analysis of suspected drugs based on the food and drug administration adverse event reporting system
by: Yan Liu, et al.
Published: (2023)

Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: A retrospective review
by: Ambika Nohria, BA, et al.
Published: (2024)

Identification of cutaneous immune-related adverse events by International Classification of Diseases codes and medication administration
by: Wenxin Chen, BS, et al.
Published: (2022)

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases
by: Qiaofang Liang, et al.
Published: (2024)

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system
by: Jiawei Zhao, et al.
Published: (2024)

Analysis of the Association of Administration of various glucocorticoids with development of acute pancreatitis using US Food and Drug Administration adverse event reporting system (FAERS)
by: Daisuke Nango, et al.
Published: (2019)

Psoriasis is associated with increased risk of other autoimmune diseases: A retrospective case-control study using the All of Us research database
by: Priya Marella, MBA, et al.
Published: (2024)

Association of anxiolytic drugs with Torsade de Pointes: a pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System
by: Zahid Ali, et al.
Published: (2024)

Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia
by: Michael G. Buontempo, BS, et al.
Published: (2023)

The United States Food and Drug Administration's Platform Technology Designation to Expedite the Development of Drugs
by: Sarfaraz K. Niazi
Published: (2024)

Dermoscopy of onychodystrophy in a patient with connective tissue disease
by: Claire Stewart, BA, et al.
Published: (2020)

Current state of knowledge about spironolactone-induded gynecomastia. Review 2024
by: Oliwia Kamila Iszczuk, et al.
Published: (2024)

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis
by: Zheng Zhang, et al.
Published: (2024)

An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021
by: Xiaotong Li, et al.
Published: (2023)

Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study
by: Ahmad Shahin, BS, et al.
Published: (2023)

Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study
by: Brigitte Dréno, et al.
Published: (2024)

Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)
by: Hardeep S. Ahdi, et al.
Published: (2023)

Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system
by: Xiangyu Sun, et al.
Published: (2024)

Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
by: Wei Wei, et al.
Published: (2023)

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
by: Stefania Chiappini, et al.
Published: (2023)

Analysis of Adverse Events and Medical Errors in Long-Term Hormone Treatments for Endometriosis: A Study Based on the US Food and Drug Administration Event Reporting System
by: Zhang Y, et al.
Published: (2022)

Efficacy of spironolactone in treating hidradenitis suppurativa in women of childbearing age: a single-center retrospective analysis
by: Suma V. Gangidi, BS, et al.
Published: (2024)

Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis
by: Yiming Li, et al.
Published: (2024)

Unusual Route of Buprenorphine Administration: An Alternative Approach for Bypassing Adverse Drug Reactions
by: Azadeh Nazari, MD, Ph.D, et al.
Published: (2019)